Personalized mRNA vaccine for rhabdomyosarcoma that has stopped responding
Part of Cancer clinical trials.
This trial tests a personalized mRNA vaccine for people with rhabdomyosarcoma that hasn't responded to standard treatments. The vaccine is made to teach your immune system to fight your specific cancer, which might slow or stop the tumor from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rhabdomyosarcoma, a cancer that starts in muscle tissue, that has been confirmed by a biopsy or genetic test.
- You need to be at least 6 years old.
- You should have no available treatment that works, or the standard treatments are not able to help you without hurting your quality of life.
- Doctors expect you to live at least another 6 months.
- You need to be generally active and able to take care of yourself (a score of 0 or 1 on the ECOG scale).
- You cannot have an active autoimmune disease or uncontrolled heart problems, and you cannot have another untreated cancer (except for certain cured skin, cervix, or bladder cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your tumor's unique gene fusion. It's for people with certain sarcomas that have spread and are now in remission or stable after standard treatment. The vaccine aims to help your immune system keep the cancer from coming back.
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
This trial tests a personalized mRNA vaccine (RH125) designed to train your immune system to attack your cancer. It is for people with advanced solid tumors that have not responded to standard treatments, and it aims to see if the vaccine is safe and helpful.
This trial tests a personalized mRNA vaccine made from your tumor's unique markers (neoantigens) to train your immune system to fight cancer. It is for people with advanced solid tumors who have not had gene therapy and are healthy enough for the vaccine.
This study tests a personalized vaccine made from your tumor's unique mutations, combined with special immune cells grown from your blood, to treat advanced sarcoma (bone or soft tissue cancer) that did not respond to initial treatment. The goal is to help your immune system recognize and attack cancer cells.
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.